Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce earnings of $0.93 per share for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Collegium Pharmaceutical’s earnings, with estimates ranging from $0.90 to $0.98. Collegium Pharmaceutical reported earnings per share of $0.32 during the same quarter last year, which would suggest a positive year-over-year growth rate of 190.6%. The business is scheduled to issue its next earnings report on Thursday, November 4th.
On average, analysts expect that Collegium Pharmaceutical will report full year earnings of $3.74 per share for the current year, with EPS estimates ranging from $3.65 to $3.87. For the next year, analysts anticipate that the company will report earnings of $4.21 per share, with EPS estimates ranging from $4.00 to $4.45. Zacks’ earnings per share calculations are an average based on a survey of sell-side research analysts that that provide coverage for Collegium Pharmaceutical.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, August 5th. The specialty pharmaceutical company reported $0.27 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.07). The business had revenue of $82.94 million during the quarter, compared to analyst estimates of $84.29 million. Collegium Pharmaceutical had a net margin of 32.73% and a return on equity of 22.59%.
Shares of NASDAQ COLL traded up $0.27 during mid-day trading on Wednesday, reaching $20.00. The company’s stock had a trading volume of 270,011 shares, compared to its average volume of 389,418. The stock has a 50-day moving average of $21.49 and a two-hundred day moving average of $22.72. The stock has a market capitalization of $711.28 million, a P/E ratio of 7.35, a P/E/G ratio of 0.71 and a beta of 0.89. The company has a debt-to-equity ratio of 0.89, a quick ratio of 1.32 and a current ratio of 1.40. Collegium Pharmaceutical has a 1-year low of $17.24 and a 1-year high of $26.91.
Hedge funds have recently made changes to their positions in the business. Captrust Financial Advisors purchased a new position in Collegium Pharmaceutical during the first quarter worth about $27,000. PNC Financial Services Group Inc. boosted its stake in Collegium Pharmaceutical by 245.9% during the second quarter. PNC Financial Services Group Inc. now owns 1,266 shares of the specialty pharmaceutical company’s stock worth $30,000 after buying an additional 900 shares during the period. Royal Bank of Canada boosted its stake in shares of Collegium Pharmaceutical by 344.3% in the second quarter. Royal Bank of Canada now owns 3,110 shares of the specialty pharmaceutical company’s stock valued at $74,000 after purchasing an additional 2,410 shares during the period. Shell Asset Management Co. purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $99,000. Finally, Ensign Peak Advisors Inc purchased a new position in shares of Collegium Pharmaceutical in the first quarter valued at approximately $102,000.
Collegium Pharmaceutical Company Profile
Collegium Pharmaceutical, Inc operates as a pharmaceutical company. The firm engages in the development and planning to commercialize next generation, abuse-deterrent products for the treatment of patients suffering from chronic pain and other diseases. Its products include Xtampza ER, Nucynta ER and Nucynta IR.
Recommended Story: Understanding debt-to-equity ratio in fundamental analysis
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.